<DOC>
	<DOCNO>NCT02440035</DOCNO>
	<brief_summary>The purpose study assess safety tolerability intramuscular homologous heterologous prime-boost regimen Ad35.RSV.FA2 ( human adenovirus-vectored vaccine candidate ) Ad26.RSV.FA2 healthy participant .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Immunogenicity Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 Healthy Adult Participants</brief_title>
	<detailed_description>This single-center , randomize ( study medication assign participant chance ) , placebo-controlled ( inactive substance ; pretend treatment [ drug ] compare clinical trial drug test drug real effect ) , double-blind ( neither researcher participant know treatment participant receive ) Phase 1 study healthy participant . The study comprise 4-week screening period ; vaccination participant Days 1 , 85 , , 169 ; 28-day follow-up period perform vaccination final visit Day 323 351 . Participants randomly assign one 4 treatment group ( Group 1/2/3/4 ) receive either Ad35.RSV.FA2 Ad26.RSV.FA2 placebo . The study duration approximately 52 week . Blood sample immunogenicity collect . Participant 's safety evaluate throughout study .</detailed_description>
	<criteria>Participant must good health , without significant medical illness , basis physical examination , medical history , vital sign measurement , 12lead electrocardiogram ( ECG ) perform screen Participant must meet protocol define laboratory criterion within 28 day Day 1 Before randomization , woman must either ; Not childbearing potential : postmenopausal surgically sterilize ; childbearing potential practicing effective method birth control vaccination 3 month last vaccination . Women , heterosexually active screening , must agree utilize highlyeffective method birth control become heterosexually active 3 month receive last dose study vaccine A woman must negative serum pregnancy test ( betahuman chorionic gonadotropin [ betahCG ] ) screen visit , negative urine pregnancy test prevaccination Day 1 A woman must agree donate egg ( ovum , oocytes ) purpose assist reproduction 3 month receive last dose study vaccine . A man must agree donate sperm 3 month receive last dose study vaccine Participant body mass index ( BMI ) less equal ( &lt; = ) 19 great equal ( &gt; =30 ) kilogram per square meter ( kg/m2 ) Participant clinically significant acute chronic medical condition , opinion investigator , would preclude participation ( e.g . history seizure disorder , bleeding/clotting disorder , autoimmune disease , active malignancy , poorly control asthma , active tuberculosis systemic infection ) Participant major surgery within 4 week prior randomization plan major surgery course study Participant chronic active hepatitis B hepatitis C infection , document hepatitis B surface antigen hepatitis C antibody , respectively Participant human immunodeficiency virus ( HIV ) type 1 type 2 infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Healthy Participants</keyword>
	<keyword>Ad35.RSV.FA2</keyword>
	<keyword>JNJ-61187191</keyword>
</DOC>